BMS expands Krazati’s FDA label to include colorectal cancer
Pharmaceutical Technology
JUNE 24, 2024
The KRAS inhibitor, Krazati, is expected to generate $1.3bn in global sales in 2029, as per GlobalData’s analysis.
52 
Lilly’s Olumiant okayed in alopecia, with Pfizer, Concert in hot pursuit
pharmaphorum
JUNE 14, 2022
The approval comes despite scrutiny of the safety of the JAK inhibitor class by the FDA, with the risk of heart-related issues leading to warnings being applied to the labels of Olumiant and other drugs in the class including Pfizer’s Xeljanz (tofacitinib) and AbbVie’s Rinvoq (upadacitinib).
Join 5,000+
Insiders
Sign Up for our Newsletter
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Trending Sources
Seeking Ofev successor, Boehringer takes PDE4B drug into phase 3
pharmaphorum
OCTOBER 26, 2022
billion a 25% gain in the prior year and fuelled in part by extensions to its label to include other progressive ILDs. Ofev is, however, heading for patent expiry in 2029, and Boehringer is looking to BI 1015550 to maintain the franchise beyond that date, and also to improve the treatment of IPF, which remains incurable.
Novo Nordisk blockbuster Ozempic boasts 23% sales surge in 2023
Pharmaceutical Technology
APRIL 28, 2023
In 2022, US sales of Ozempic contributed to 65% of global sales; this is expected to continue, with the US market forecast to continue capturing the majority of sales, generating $71bn between 2023–2029. It is forecast that Ozempic will sustain its sales growth over the next five years, with an expected annual sales figure of $17bn in 2029.
CMS Finalizes Guidance on Medicare Part D Manufacturer Discount Program
The FDA Law Blog
DECEMBER 3, 2023
The manufacturer’s agreement must cover all its labeler codes that contain an applicable drug or a selected drug. All labeler codes that are covered by Discount Program agreements will be distributed to PDP sponsors and posted on the CMS website. had Part D expenditures on or before August 16, 2022).
T2D market growth driven by novel GLP-1RAs and once-weekly basal insulin therapies
Pharmaceutical Technology
JANUARY 10, 2023
billion in 2029, with drug sales almost doubling at a compound annual growth rate (CAGR) of 11.5%. Specifically, across all the major classes there are significant developments, label updates, and biosimilar launches that are driving their growth. billion in 2029, although its sales growth is likely to continue beyond 2029.
AbbVie files Vraylar as add-on therapy for depression in US
pharmaphorum
FEBRUARY 23, 2022
It also includes data from a long-term, open-label study that focused on the safety and tolerability of the drug over 26 weeks. Analysts at GlobalData are predicting peak sales of $383 million for the drug in 2029. Vraylar is now one of AbbVie’s fastest-growing products with sales expected to reach around $2.2
Let's personalize your content